Clinical trial
Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation
NCT03666559 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Treatment With Azacitidine of Recurrent Gliomas With IDH1/2 Mutation
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- September 22, 2020
- Completion date
- March 23, 2024
- Enrollment
- 8 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
recurrent idh1/2 mutated glioma